Barclays analyst Matt Miksic raised the firm’s price target on Bausch + Lomb to $19 from $18 and keeps an Equal Weight rating on the shares. The company delivered very strong growth in Q2 but given increased operating investment in new product launches, significant margin gains will be pushed out until late 2024 and 2025, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BLCO:
- Bausch + Lomb files automatic mixed securities shelf
- Bausch + Lomb raises FY23 revenue view to $3.95B-$4.00B from $3.90B-$3.95B
- Bausch + Lomb reports Q2 adjusted EPS 18c, consensus 14c
- BLCO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Bausch Health price target raised to $9 from $8 at RBC Capital